NCT01884623已完成3 期
Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Failure free survival (FFS)
研究概览
简要总结
To test whether cetuximab improves efficacy/tolerance as compared to methotrexate in first line treatment of unfit patients ³ 70 years old with recurrent and /or metastatic HNSCC. Efficacy assessed by failure free survival
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 70 or over
- •Included in ELAN-ONCOVAL study and considered as "Unfit" by geriatric evaluation done in this study
- •Histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral cavity, oropharynx, hypopharynx, larynx.
- •Recurrence and/or metastatic disease not suitable for local therapy.
- •At least one measurable lesion (RECIST 1.1) by CT or MRI.
- •No brain metastasis.
- •Clearance of creatinine >= 50ml/mn (MDRD).
- •Adequate haematological functions defined as follows: absolute neutrophil count > 1.5 x 109/l, platelet > 100 x 109/l, hemoglobin >= 9.5 g/dl
- •Adequate hepatic functions with serum total bilirubin <1.25 Upper limit of normal range (ULN); SGOT/SGPT < 5 ULN; AP < 5 ULN
- •Life expectancy > 12 weeks.
- •Males of reproductive potential must agree to use an effective contraceptive method during the treatment and after the end of treatment during five months.
- •Signed informed consent.
- •Affiliated to Health Insurance regimen (according to Public Health Law of August 9, 2004).
排除标准
- •Included in ELAN-ONCOVAL study and considered as "Fit" by geriatric evaluation
- •Patients with nasopharyngeal cancer, paranasal sinus, or cervical lymph nodes metastasis of unknown origin.
- •Prior systemic chemotherapy for the squamous cell carcinoma of head and neck, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry.
- •Prior anti-EGFR therapy, except if given in association with radiotherapy for squamous cell carcinoma of head and neck which was completed more than 12 months prior to study entry.
- •Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before study entry.
- •Brain metastasis
- •Active infection including tuberculosis and HIV infection.
- •Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV), unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias
- •Concomitant immunotherapy or antitumoral hormonotherapy.
- •Requirement for treatment with any of the prohibited concomitant medications listed in SPC of Cetuximab and Methotrexate. In particular, acetylsalicylic acid used at analgesic, antipyretic or anti-inflammatory doses (see Section 6.3.2).
- •Malignancies within 5 years prior to randomization, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix
- •Known allergic hypersensitivity to cetuximab or known positive results of tests for IgE antibodies against cetuximab (α-1-3-galactose) and/or methotrexate or any of their excipients.
- •Other severe acute or chronic psychiatric or medical condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient's safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
研究组 & 干预措施
Cetuximab
Experimental
Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
干预措施: Cetuximab (Drug)
Methotrexate
Active Comparator
Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
干预措施: Methotrexate (Drug)
结局指标
主要结局
Failure free survival (FFS)
时间窗: From randomization to the first event among progression, treatment stop, whatever the cause, loss of 2 points or more in ADL scale and death assessed up to 16 months
Composite criteria of efficacy and tolerance: Failure free survival (FFS) defined as time from randomization to the first event among progression (defined by RECIST criteria), treatment stop (whatever the cause), loss of 2 points or more in Activities in Daily Living (ADL) scale and death (whatever the cause). Patients who don't have any of these events are censored at the date of last follow-up.
次要结局
- Overall survival (OS)(From randomization to death from any cause assessed up to 1 months)
- Progression free survival (PFS)(From randomization to progression assessed up to 16 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric CancerGastric CancerNCT00678535Merck KGaA, Darmstadt, Germany904
已完成
3 期
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck CancerCarcinoma, Squamous Cell of Head and NeckNCT02383966Merck KGaA, Darmstadt, Germany243
已完成
3 期
Cetuximab and Best Supportive Care Compared with Best Supportive Care Alone in Treating Patients with Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer.Colorectal CancerACTRN12606000112561ational Cancer Institute of Canada500
招募中
3 期
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNSquamous Cell Carcinoma of the Head and NeckNCT05751512Lepu Biopharma Co., Ltd.180
已完成
3 期
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsSquamous Cell Carcinoma of the Head and NeckNCT01012258Merck KGaA, Darmstadt, Germany70